ASG. Aurora Spine Corp

Aurora Spine Corporation Schedules Release of Fourth Quarter and Fiscal 2024 Financial Results

Aurora Spine Corporation Schedules Release of Fourth Quarter and Fiscal 2024 Financial Results

CARLSBAD, California, April 23, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced it will issue its financial results for the fourth quarter and fiscal year ended December 31, 2024, on Monday, April 28, 2025, after market hours. Management will host a conference call for investors on Tuesday, April 29, 2025 at 11:00 am ET/8:00am PT to discuss the results with investors.

Additionally, the Company wishes to clarify that the management information circulars issued in connection with its 2023 and 2024 annual meetings of shareholders inadvertently referenced a prior version of the Company’s stock option plan. The updated plan, which has been in effect since its approval by the board in 2022, included certain amendments that were not described in the circulars. The Company intends to include the correct version of the plan in the materials for its upcoming annual general meeting of shareholders, details of which will be announced in due course.

Fourth Quarter and Fiscal Year 2024 Conference Call Details

Date and Time: Tuesday, April 29, 2025, at 11:00 a.m. ET / 8:00 a.m. PT

Call-in Information: Interested parties can access the conference call by dialing (844) 861-5497 or (412) 317-5794.

Webcast: Interested parties can access the conference call via a live webcast, which is available via the following link: .

Replay: A teleconference replay of the call will be available until May 6, 2025, at (877) 344-7529 or (412) 317-0088, replay access code 5737353. Additionally, a replay of the webcast will be available at for 90 days.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at -spine.com or

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Contact:

Aurora Spine Corporation

Trent Northcutt

President and Chief Executive Officer

(760) 424-2004

Chad Clouse

Chief Financial Officer

(760) 424-2004

Investor Contact

Adam Lowensteiner

Lytham Partners

(646) 829-9702



 
EN
23/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aurora Spine Corp

 PRESS RELEASE

Aurora Spine Corporation Announces Fourth Quarter and Fiscal Year 202...

Aurora Spine Corporation Announces Fourth Quarter and Fiscal Year 2024 Financial Results -Company reports record revenue of $17.6 million for FY 2024, an increase of 21% – -Company to host conference call Today, Tuesday, April 29th at 11am ET/8am PT – NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced it...

 PRESS RELEASE

Aurora Spine Corporation Schedules Release of Fourth Quarter and Fisca...

Aurora Spine Corporation Schedules Release of Fourth Quarter and Fiscal 2024 Financial Results CARLSBAD, California, April 23, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced it will issue its financial results for the fourth quarter and fiscal year ended December 31, 2024, on Monday, April 28, 2025, after market hours. Management will host a conference call for investors on Tuesday, April 29, 2025 at 11:00 am ET/8:00a...

 PRESS RELEASE

Aurora Spine Announces the Resignation of Board Director James Snow

Aurora Spine Announces the Resignation of Board Director James Snow CARLSBAD, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that James Snow, a board member for Aurora Spine since its inception in 2012, has resigned from the Aurora Spine Board of Directors to take on the role of Regulatory Affairs and Quality Assurance Manager for the Company. Mr. Snow will use his 20+ years of medical device expe...

 PRESS RELEASE

Aurora Spine Announces Publication of Biomechanical Study Demonstratin...

Aurora Spine Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™ Sacroiliac Fusion System CARLSBAD, California, April 02, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the publication of a new clinical study titled "Fixation of the Sacroiliac Joint: A Cadaver-Based Concurrent-Controlled Biomechanical Comparison of Posterior Interposition and Posterolateral Transosseous Techniques" i...

 PRESS RELEASE

Aurora Spine Announces FDA 510(k) Clearance for the AERO™ Facet Fusion...

Aurora Spine Announces FDA 510(k) Clearance for the AERO™ Facet Fusion System CARLSBAD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company’s newest product, the AERO™ Facet Fusion System. The AERO MIS Facet Fusion System is a novel, patent-pending device designed to provide a minimally invasive solution for patients suffering fr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch